Health & Wellness
Psycheceutical Bioscience, Inc.
Safer psychedelic medicines for better mental health treatments
Fort Lauderdale,
FL
Investment type:
Equity
(Priced Round)
Target raise:
$50,000
- $5,000,000
Minimum investment:
$250
$250
End date:
Mar 16, 2024
Mar 16, 2024
ended
Share
Highlights
- Developing two patented delivery technologies to increase the safety and efficacy of psychedelics
- Phase I trial first dosing results of ketamine topical for PTSD shown to be safe and well-tolerated
- Observational data of ketamine topical for PTSD showed 80% of patients experienced symptom relief
- Kevin Harrington, celebrity Shark Tank star, has invested and joined as Strategic Advisor
Our Story
Psycheceutical is developing two next-generation patented delivery technologies designed to increase the safety and efficacy of psychedelic compounds, with the goal of providing better treatment options to those suffering from mental health disorders. Both technologies are designed to cross or avoid the blood brain barrier, delivering medications directly to the brain while reducing "trippy" side effects as well as toxicity to the stomach, liver, and kidneys.
Our Ambition
In five years, we believe that Psycheceutical will be working with the world's largest pharmaceutical companies to provide accurate and safe dosing of psychedelic medicines for a number of mental health conditions. It is also our intention to have our own FDA-approved formulations delivered through our patented technologies.